Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)

BACKGROUND: Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) was a randomized, open‐label, phase 2 trial evaluating first‐line cabozantinib versus sunitinib in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ronald C., Choueiri, Toni K., Feuilly, Marion, Meng, Jie, Lister, Johanna, Marteau, Florence, Falchook, Aaron D., Morris, Michael J., George, Daniel J., Feldman, Darren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756547/
https://www.ncbi.nlm.nih.gov/pubmed/33022096
http://dx.doi.org/10.1002/cncr.33169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756547/
https://www.ncbi.nlm.nih.gov/pubmed/33022096
http://dx.doi.org/10.1002/cncr.33169

Ejemplares similares